Csl
CSL Limited, commonly referred to as CSL, is a global biotechnology leader headquartered in Australia. Founded in 1916, the company has evolved significantly, establishing a strong presence in key operational regions including North America, Europe, and Asia-Pacific. Specialising in the development of innovative therapies for rare and serious diseases, CSL focuses on areas such as immunology, haematology, and respiratory health. The company is renowned for its core products, including immunoglobulins and clotting factors, which are distinguished by their high quality and efficacy. CSL's commitment to research and development has positioned it as a market leader, with notable achievements such as being consistently ranked among the top biopharmaceutical companies globally. With a rich history and a dedication to improving patient outcomes, CSL continues to set benchmarks in the biotechnology industry.
DitchCarbon Score
How does Csl's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Csl's score of 31 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Csl's reported carbon emissions
In 2024, CSL Limited reported total greenhouse gas emissions of approximately 351,000,000 kg CO2e, comprising about 130,000,000 kg CO2e from Scope 1 and about 221,000,000 kg CO2e from Scope 2 emissions. This reflects a slight increase from 2023, where total emissions were about 336,000,000 kg CO2e, with Scope 1 at approximately 113,000,000 kg CO2e and Scope 2 at about 223,000,000 kg CO2e. CSL has set ambitious climate commitments, aiming for a 40% reduction in absolute Scope 1 and 2 emissions by 2030, using the average annual emissions from fiscal years 2019 to 2021 as a baseline. This target underscores CSL's commitment to sustainability within the pharmaceuticals, biotechnology, and life sciences sector. While CSL has not disclosed Scope 3 emissions data, their focus on reducing Scope 1 and 2 emissions demonstrates a proactive approach to mitigating their carbon footprint. The company is committed to these near-term targets, reflecting a strategic alignment with global climate initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 0,000,000,000 | 0,000,000,000 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Csl is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
